FDA Grants Survodutide Breakthrough Therapy Designation for MASH
The FDA granted breakthrough therapy designation to survodutide, a dual glucagon/GLP-1 receptor agonist by Boehringer Ingelheim, for treating adults with MASH.
#boehringer-ingelheim
1 story